Are you looking to add some growth shares to your investment portfolio in June?
If you are, then the four highly rated ASX growth shares listed below could be worth considering.
Here’s what you need to know about them:
Aristocrat Leisure Limited (ASX: ALL)
The first ASX growth share that could be a buy is Aristocrat Leisure. It is one of the world’s leading gaming technology companies. It has a world class portfolio of pokie machines, a lucrative digital business, and a growing real money gaming business.
Analysts at Citi are very positive on the company. Particularly given its strong performance in the first half of FY 2024 and management’s confidence in its outlook.
Citi has a buy rating and $53.00 price target on Aristocrat Leisure’s shares.
Pro Medicus Limited (ASX: PME)
Goldman Sachs thinks Pro Medicus is a top ASX growth share to buy. It is a leading provider of radiology information systems (RIS), Picture Archiving and Communication Systems (PACS), and advanced visualisation solutions across the globe.
Goldman is very positive on the company’s outlook. It notes that it sees “PME as the clear incumbent technology leader in a growing market with a strong financial profile and significant AI upside.”
The broker has a buy rating and $136.00 price target on its shares.
ResMed Inc. (ASX: RMD)
A third ASX growth share that has been tipped as a buy is ResMed. It is a sleep treatment-focused medical device company.
ResMed has been growing at a strong rate for over a decade. But if you thought its growth was coming to an end, think again. That’s because its industry-leading products have a massive market opportunity. Management estimates that there are 1 billion people impacted by sleep apnoea worldwide, with only ~20% of these sufferers currently diagnosed.
Ord Minnett is bullish on ResMed and has an accumulate rating and $40.00 price target on its shares.
TechnologyOne Ltd (ASX: TNE)
A final ASX growth share for investors to look at in June is TechnologyOne. It is Australia’s largest enterprise software company with locations across six countries. It provides a global SaaS ERP solution that transforms business and makes life simple for users.
Analysts at Morgans were impressed with the company’s half year results this month. In fact, the broker believes that the company’s profit growth is about to go up a gear. Particularly given its successful transition to a software-as-a-service business model.
Morgans currently has an add rating and $20.50 price target on its shares.
The post 4 ASX growth shares to buy to supercharge your portfolio in June appeared first on The Motley Fool Australia.
Should you invest $1,000 in Aristocrat Leisure Limited right now?
Before you buy Aristocrat Leisure Limited shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Aristocrat Leisure Limited wasn’t one of them.
The online investing service heâs run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
See The 5 Stocks
*Returns as of 5 May 2024
More reading
- Why Playside Studios, Pro Medicus, Strike Energy, and Winsome shares are charging higher
- 2 no-brainer ASX 200 shares to buy next week
- Here’s how the ASX 200 market sectors stacked up last week
- Brokers name 3 ASX shares to buy now
- 2 ASX 200 shares trading ex-dividend next week
Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in Pro Medicus, ResMed, and Technology One. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group, Pro Medicus, ResMed, and Technology One. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Pro Medicus and Technology One. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
Leave a Reply